Sigma-1 receptor:a new therapeutic target for major depressive disorder
10.7644/j.issn.1674-9960.2024.07.012
- VernacularTitle:Sigma-1受体:抑郁症治疗的新靶点
- Author:
Honglei CHEN
1
;
Peng REN
;
Yunfeng LI
Author Information
1. 南华大学衡阳医学院军事科学院军事医学研究院研究生协作培养基地,湖南衡阳 421001
- Keywords:
Sigma-1 receptor;
depressive disorder;
target;
mechanism;
clinical study
- From:
Military Medical Sciences
2024;48(7):554-560
- CountryChina
- Language:Chinese
-
Abstract:
Major depressive disorder(MDD)is a mental disease characterized by persistent depression,lack of interest and impaired cognitive function.Antidepressants currently availablein clinic are effective but accompanied by many adverse reactions,such as slow onset,cognitive impairment,sexual dysfunction.Therefore,novel antidepressant targets and therapeutic strategies with rapid onset of action,cognitive enhancement and low adverse effects have increasingly become a promising sphere of research.Studies have suggested that Sigma-1 receptor plays an important role in combating depression by regulating inflammatory response,excitation/inhibition balance and endoplasmic reticulum homeostasis.Moreover,Sigma-1 receptor agonists may have the advantages of rapid onset,enhanced cognition and low adverse reactions,which show good prospects for the development of new antidepressants.This article reviews the research progress related to Sigma 1 receptors in the regulatory mechanism and treatments for depression in the hopes of providing new insights into new antidepressants.
